Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590266 | 0.78 | AR (0.45) | PGRAR | |
| SCHEMBL14727014 | 0.77 | P2RX3 (0.32) | — | |
| SCHEMBL2586500 | 0.77 | RXRA (0.40) | ALDH1A1 | |
| SCHEMBL17970391 | 0.73 | MGLL (0.35) | — | |
| SCHEMBL15723852 | 0.72 | CDC7 (0.43) | KIF11ALDH1A1PDE2ASLC6A2SLC6A4 | |
| SCHEMBL18585239 | 0.72 | MEN1 (0.38) | PGRAR | |
| SCHEMBL21438892 | 0.72 | SLC6A2 (0.32) | SLC6A2SLC6A4 | |
| SCHEMBL21438922 | 0.71 | HCAR3 (0.41) | — | |
| SCHEMBL14909878 | 0.70 | MAPT (0.39) | DDR1KIF11GRM2ALDH1A1 | |
| SCHEMBL20655579 | 0.69 | ALDH1A1 (0.44) | KIF11ALDH1A1PDE2ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| EP-2773754-B1 | Compounds for use in the treatment of T-cell mediated diseases | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-08-03 | — | — | EP | disclosed |
| US-9402836-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20130345200-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| CN-102970869-A | Indoles | GLAXOSMITHKLINE LLC | 2013-03-13 | — | — | CN | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345200-A1 | INDOLES | IDO1, IDO2, INMT | DDR1 2938/4885KIF11 935/4885GRM2 3399/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | DDR1 3011/4885KIF11 1027/4885GRM2 3447/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | DDR1 2938/4885KIF11 935/4885GRM2 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.